Skip to main content

Michael G. Kurilla, M.D., Ph.D.

Director

Division of Clinical Innovation

Office of the Director

Photo of Michael G. Kurilla, M.D., Ph.D.

Biography

Michael Kurilla is the director of the Division of Clinical Innovation at NCATS. In this capacity, he oversees the Clinical and Translational Science Awards (CTSA) Program, which supports innovative solutions to advance the efficiency, quality and impact of translational science, with the ultimate goal of getting more treatments to more patients more quickly. Prior to joining NCATS, Kurilla served as the director of the Office of Biodefense Research Resources and Translational Research within the National Institute of Allergy and Infectious Diseases (NIAID), where he focused on translational efforts toward infectious disease product development, including vaccines, therapeutics and diagnostics, with emphasis on biodefense and emerging infectious disease threats. Prior to joining NIAID in 2003, Kurilla was an associate director for infectious diseases at Wyeth. He also worked in antimicrobials at DuPont and on clinical microbiology and molecular pathology at the University of Virginia Health Sciences Center.

Kurilla received his M.D. and his Ph.D. in microbiology and immunology from Duke University. He was a postdoctoral research fellow at Harvard Medical School and completed a residency in pathology at Brigham and Women’s Hospital. He received a B.S. in chemistry from the California Institute of Technology.

Research Topics

Kurilla’s research interests include all facets of translational science, especially innovative and novel interventional concepts requiring additional input from regulatory science to enable viable, robust developmental pathways.

Last updated on March 29, 2024